1. ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
- Author
-
Zachary R. Schoepflin, MD, Emmeline Academia, PharmD, Soravis A. Osataphan, MD, Deepa Rangachari, MD, Sheida Sharifi, MD, PhD, Paul A. VanderLaan, MD, PhD, and Daniel B. Costa, MD, PhD
- Subjects
Lung cancer ,ALK ,Deletion ,Alectinib ,Case report ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
ALK internal deletions of nonkinase domain exons occur in 0.01% of lung cancers with ALK genomic aberrations. We report a lung adenocarcinoma with a previously undescribed somatic ALK deletion of exons 2 to 19 with dramatic and sustained (>23 mo) response to alectinib. Our and other reported cases with ALK nonkinase domain deletions (between introns and exons 1–19) can display positive results in nonsequencing-based lung cancer diagnostic tests (such as immunohistochemistry) used to screen for more common ALK rearrangements. This case report emphasizes that “ALK-driven” lung cancers should be expanded to encompass those harboring not only ALK rearrangements with other genes but also ALK nonkinase domain deletions.
- Published
- 2023
- Full Text
- View/download PDF